Supported by Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Amarin Corp, and Alliance Partners with Leading Medical Associations
The National Triglyceride Alliance is proud to announce its official launch, marking a pivotal step in advancing education and awareness about the critical role of triglycerides in metabolic health. With the support of Founding Sponsor, Ionis, National Sponsor, Arrowhead Pharmaceuticals, and Local Sponsor, Amarin Corp, the NTA aims to transform clinical practice through education and advocacy, empowering healthcare professionals to prioritize proactive treatment of high triglycerides – saving lives, reducing risks and revolutionizing patient care. Our vision is to create a healthcare landscape where the treatment of high triglycerides becomes a core tenet of patient care.
Health Technology Insights: Lupin Digital Health Launches Post-Procedure Care Guide
The NTA is honored to collaborate with its Alliance Manager, the American Society for Preventive Cardiology (ASPC) and esteemed Member Partners, Preventive Cardiology Nurses Association (PCNA), the National Lipid Association (NLA), the American Association for Clinical Endocrinology (AACE), the FCS Foundation, and the Foundation of the NLA (FNLA). Together, these organizations will work to provide evidence-based education, expert-driven resources, and clinical guidance to healthcare providers striving to improve patient outcomes.
Millions of Americans live with elevated triglycerides, which are a significant yet often underrecognized factor in the cause of pancreatitis and cardiovascular disease. Despite the clinical importance of managing triglyceride levels, many healthcare professionals lack the necessary education and tools to effectively manage elevated triglyceride levels. The National Triglyceride Alliance seeks to close this gap in care by fostering collaboration among industry leaders, researchers, and frontline clinicians.
Health Technology Insights: Neupath Health Secures Credit Facilities to Drive Growth
“Our mission is to bridge the knowledge divide and ensure that clinicians recognize the need to proactively manage high triglycerides and are empowered with the most up-to-date science and clinically relevant treatment approaches,” said Seth Baum, MD, MASPC, FACC, FAHA, FNLA, and Chairperson of the NTA. “With the generous support of Ionis, Arrowhead Pharmaceuticals, and Amarin, as well as the partnership of the ASPC, PCNA, NLA, the FCS Foundation, and the Foundation for the NLA, we look forward to transforming the paradigm of metabolic care, with a focus on increasing awareness of triglyceride management and its role in preventive care.”
The NTA will offer educational programs, clinical resources, and ongoing initiatives aimed at improving understanding and treatment strategies for high triglycerides. Through a combination of research dissemination, professional development, and strategic partnerships, the NTA seeks to redefine best practices in triglyceride management.
Health Technology Insights: CyPath Lung Detects Second Primary Lung Cancer in Patient
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
